Canada markets closed

Purple Biotech Ltd (PPBT)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.5410+0.0040 (+0.74%)
At close: 04:00PM EDT
0.5594 +0.02 (+3.40%)
After hours: 06:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.5370
Open0.5400
Bid0.5052 x 100
Ask0.5967 x 100
Day's Range0.5186 - 0.5797
52 Week Range0.3020 - 2.0800
Volume216,418
Avg. Volume153,634
Market Cap16.059M
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-0.9000
Earnings DateMay 17, 2024 - May 21, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
  • GlobeNewswire

    Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

    Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interim results from its randomized, controlled

  • GlobeNewswire

    Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024

    NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion a

  • GlobeNewswire

    Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

    Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to ov